PE-CF594 Rabbit anti-Human/Monkey HLA-DR Monoclonal Antibody for Flow Cytometry - P01903

Core Product Specifications and Parameters

Biological Background: HLA-DR Function and Localization

• The HLA-DR complex consists of an alpha chain (HLA-DRA) and a beta chain, functioning as an MHC class II molecule that presents antigenic peptides to CD4+ T cells, thereby driving T-helper cell activation and downstream immune responses. Related references: PMID:15265931, PMID:15322540, PMID:17334368
• It typically displays extracellular peptides of 10–30 amino acids derived from endocytosed antigens processed in lysosomes, with an aromatic or hydrophobic anchor residue at peptide position 1 essential for high-affinity binding. Related references: PMID:8145819
• In the tumor microenvironment, HLA-DR presents peptides generated from phagocytosed apoptotic tumor cells or macropinocytosed tumor proteins, implicating it in anti-tumor immunity. Related references: PMID:31495665
• Through macroautophagy, HLA-DR can also present peptides from intracellular proteins, a pathway critical for thymic T cell selection and central tolerance. Related references: PMID:17182262, PMID:23783831
• Peptide loading follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigens and 'cut first, bind later' for autoantigens. Related references: PMID:25413013
• HLA-DR is constitutively expressed on professional antigen-presenting cells (macrophages, dendritic cells, B cells) and thymic epithelial cells. Related references: PMID:15322540, PMID:23783831, PMID:31495665
• The protein localizes to the cell membrane, endoplasmic reticulum, early/late endosomes, lysosomes, and autolysosomes, reflecting its trafficking during antigen processing.
• Post-translational modifications include disulfide bonds, glycosylation, and ubiquitination; it is also involved in host-virus interactions.

Experimental Guidance and Technical Tips

• Designed for flow cytometry (FC) with PE-CF594 conjugate; consider optimal excitation/emission filters for PE-CF594 detection.
• Validated reactivity with human and cynomolgus monkey samples; when using with other species, cross-reactivity should be experimentally verified.
• Include appropriate isotype controls and Fc receptor blocking reagents to minimize nonspecific binding.
• For multi-color flow panels, confirm minimal spectral overlap and compensation settings with the fluorophore.
• As the immunogen is a recombinant protein spanning the entire HLA-DR alpha chain, the antibody likely recognizes a linear epitope conserved in native and denatured forms; consider suitability for intracellular staining if needed.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as your integrated sourcing partner for IVD raw materials, offering this anti-HLA-DR antibody as part of a broader immunology portfolio. From optimized monoclonal/polyclonal antibodies and antibody pairs for diagnostic development to bulk ancillary reagents, CamelBio streamlines procurement of quality materials for immune monitoring and oncology applications. Our expertise supports rare target sourcing, enabling your projects from concept to clinic.